Legend Biotech develops and commercializes novel cell therapies targeting hematologic malignancies and solid tumors, utilizing advanced CAR-T technology to enhance patient outcomes. The company focuses on treating intractable and incurable cancers, aiming to improve minimal residual disease negativity in patients with relapsed or refractory multiple myeloma.
Funding
Funding not disclosed
Founders
Product
Problem
Many hematologic malignancies and solid tumors are considered intractable and incurable, presenting a significant challenge for patients who have exhausted standard treatment options. These cancers often exhibit resistance to conventional therapies, leading to relapse and poor prognosis. New therapeutic approaches are needed to improve outcomes for these patients.
Solution
Legend Biotech is developing and commercializing novel cell therapies, with a focus on CAR-T technology, to treat hematologic malignancies and solid tumors. Their approach involves genetically modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that specifically targets cancer cells. These engineered CAR-T cells are then infused back into the patient, where they can recognize and destroy cancer cells, leading to improved minimal residual disease negativity and durable responses. The company's pipeline includes investigational agents and innovative technologies in personalized medicine, targeting diseases that are considered intractable and incurable.
Target Audience
The primary target audience includes patients with relapsed or refractory hematologic malignancies and solid tumors who have limited treatment options, as well as the physicians who treat them.
Features
- CAR-T cell therapy platform targeting specific cancer antigens
- End-to-end capabilities from discovery to commercialization
- Pipeline of investigational agents for hematologic malignancies and solid tumors
- Focus on improving minimal residual disease negativity
- Technology agnostic approach, exploring multiple technology platforms